Studying pigmentary glaucoma and a 120° eye drainage surgery over 6 months
Describes pigmentary glaucoma and checks how well a 120° trabeculotomy surgery works.
Plain-language title generated from the registry record
Registry title: Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy
Key facts
- Where
- Wuhan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 80 years old?
Source: NCT07713056, who can take part
Where in China
- Zhongnan Hospital of Wuhan UniversityWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhongnan Hospital
- Trial code
- NCT07713056
- Record updated
- 20 July 2026
- Original description
This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.Read full original descriptionShow less
Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy: A Case Series Study
This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.
Inclusion: Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects; Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment; Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements; Able to complete regular follow-up for at least 6 months postoperatively.
Exclusion: Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation; Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma; Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment; Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up; Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.